Akebia Therapeutics, Inc. is a United States-based biopharmaceutical company, which is focused on the development of therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company�s product candidate, AKB-6548, is in a Phase-IIb clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily, oral therapy to inhibit hypoxia-inducible factor prolyl hydroxylase, which is expected to stabilize and increase levels of HIFα and improve the production of hemoglobin and red blood cells. AKB-6899 is its second hypoxia inducible factor-prolyl hydroxylase (HIF-PH) inhibitor product candidate.